Quick answers

What is LL-37 and what is it used for in research?
LL-37 is classified within the Healing & Recovery group. Human cathelicidin fragment with antimicrobial and wound-healing activity. Active research area. Research applications focus on the pathways outlined below. All references on this page describe published research only, LL-37 is supplied for in-vitro and laboratory use, not for human consumption.
How does LL-37 work?
Primary mechanism: Cathelicidin-derived antimicrobial peptide; immune modulation. Downstream effects depend on dose, timing, and the biological system under investigation. Receptor binding and post-receptor signalling for LL-37 remain areas of active study, and several proposed effects are supported only by preclinical data.
What is the typical LL-37 research dose?
Published research protocols for LL-37 describe per-dose ranges of 100–500 mcg / day, with a weekly total near Variable, administered daily sc. Typical cycle: research dependent. These ranges reflect the literature and are not dosing recommendations for any individual.
Where can I buy LL-37 in Thailand?
LL-37 is supplied by Thailand Peptides, a Bangkok-based research-peptide supplier. Orders are placed directly via WhatsApp to the Bangkok research desk, no cart, no account, no forms. Pricing and shipping are provided on request. Open a line with the research desk →
How fast can LL-37 be delivered in Thailand?
Same-week delivery across Thailand is standard for orders confirmed within business hours (GMT+7, Monday–Saturday). Bangkok metro deliveries typically arrive within 1–3 business days; other provinces within 3–5. Regional Southeast Asia shipping is available on request.

What is LL-37?

LL-37 is a research peptide in the Healing & Recovery class. Cathelicidin-derived antimicrobial peptide; immune modulation. It is studied at per-dose ranges of 100–500 mcg / day (Variable weekly), administered daily sc over cycles of research dependent. Supplied in Thailand by Thailand Peptides, Bangkok-based, research use only.

Human cathelicidin fragment with antimicrobial and wound-healing activity. Active research area.

Published and preclinical data are summarised below; dose ranges shown reflect protocols in the research literature and should be interpreted accordingly.

How does LL-37 work?

LL-37 is the sole human cathelicidin-derived antimicrobial peptide, a 37-residue amphipathic α-helical peptide. It disrupts bacterial membranes via electrostatic interaction with anionic lipids and also modulates innate immunity through effects on chemokine release, epithelial wound-healing signalling, and angiogenesis. Active research covers infection, wound healing, and tumour biology.

Receptor binding affinity and post-receptor signalling for LL-37 remain areas of active investigation; several proposed effects within the Healing & Recovery class are currently supported only by in-vitro or rodent data, and should be interpreted accordingly.

LL-37 pharmacokinetics

Half-life
Short systemic half-life; PK parameters are an active research area and depend on formulation.
Bioavailability
SC and topical routes both used in research; IV route reported in septic-shock research.
Route of administration
Subcutaneous injection in research protocols; topical formulations in wound-healing work.
Metabolic clearance
Rapid proteolytic clearance; some fragments retain partial activity.

LL-37 research timeline

  1. 2012 Vandamme et al., comprehensive summary of LL-37 as a factotum human cathelicidin peptide (Cell Immunol).

LL-37 dosage & protocol

Reference protocol for LL-37 (research context only, drawn from published literature):

  • Per dose: 100–500 mcg / day
  • Weekly total: Variable
  • Frequency: Daily SC
  • Cycle: Research dependent

LL-37 injection & handling

Reconstitution
Typical research prep: 5 mg vial + 2 mL bacteriostatic water, yielding 2.5 mg/mL.
Storage
Lyophilised powder at −20 °C; reconstituted solution refrigerated and used within 2–4 weeks.
Sites used in the research literature
Subcutaneous abdomen in systemic research; topical application to wound bed in local-delivery research.

Handling notes reflect methods used in published research protocols, not medical dosing guidance.

Order LL-37
Ready to order? WhatsApp the Bangkok research desk, pricing and availability confirmed within the chat.
Ask about LL-37 ≥98% HPLC purity · supplier COA on file · Bangkok-based

Stacking LL-37

Commonly referenced pairing with LL-37: Monotherapy. Stacking rationale should be grounded in complementary mechanisms, not additive speculation; interactions at shared receptors or enzymatic pathways should be accounted for. Both compounds in a LL-37 stack are supplied by Thailand Peptides on the same order via the Bangkok research desk.

Contraindications

Autoimmune conditions. Additional caution is warranted in individuals with hepatic or renal impairment, endocrine disorders, or concurrent pharmacotherapy affecting the pathways described above.

Further reading

Citations

  1. Vandamme D, et al. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol. 2012. PMID: 23246832

References curated from PubMed. Additional literature summarised in the Thailand Peptides research library.